Tenax Therapeutics Inc. (TENX)
Symbol Info
Listed Symbol TENX
Name Tenax Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-9.05
Price Info
21 Day Moving Average $1.2791
21 Day EMA $1.263360
50 Day Moving Average $1.3221
50 Day EMA $1.331070
200 Day EMA $2.195060
200 Day Moving Average 1.746970
52 Week High $6.39
52 Week Low $1.03
52 Week Change $-77.254900
Alpha -0.046038
Beta 1.3647
Standard Deviation 0.229704
R2 0.042490
Periods 60
Share Information
10 Day Average Volume 60,549
20 Day Average Volume 54,639
30 Day Average Volume 71,977
50 Day Average Volume 88,180
Outstanding Shares 6,193,229
Float Shares 4,574,690
Percent Float 73.87%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 23
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 676,019
Institute Holdings Percent 16.300000
Institute Sold Previous 3 Months 29,759
Insider Holdings Date 2019-07-31
Insider Bought Previous 3 Months -
Insider Holdings Percent 26.10%
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,618,539
Price Change
7 Day Price Change $-0.11
7 Day Percent Change -8.66%
21 Day Price Change $-0.1600001
21 Day Percent Change -12.12%
30 Day Price Change $-0.2800001
30 Day Percent Change -19.44%
Month To Date Price Change $-0.15
Month To Date Percent -11.45%
90 Day Price Change $-0.2
90 Day Percent Change -14.71%
Quarter To Date $-0.22
Quarter To Date Percent -15.94%
180 Day Price Change $-0.09
180 Day Percent Change -7.20%
200 Day Price Change $-0.03
200 Day Percent Change -2.52%
Year To Date $-0.05
Year To Date Percent -4.13%
Profile
Description Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. The company develops novel product candidates such as Levodimendan IV that have the potential to address various critical care conditions with a high unmet medical need. Its drugs help in the reduction of morbidity and mortality in cardiac surgery patients. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure.
Details
Issue Type CS
Market Cap $7,184,146
Sec Type EQS
Auditor Cherry Bekaert LLP
Total Shares Outstanding 6,193,229
CEO Anthony A. DiTonno
Employees 10
Last Audit UE
Classification
CIK 0000034956
Industry Biotechnology
Sector Healthcare
NAICS Research and Development in Biotechnology (except Nanobiotechnology)(541714)
Info
Address ONE Copley Parkway
Suite 490
Morrisville, NC 27560
Website http://www.tenaxthera.com
Facisimile +1 919 855-2133
Telephone +1 919 855-2100
Email jesse@sternir.com
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $-3,515,673
Price To Sales -
Price To Free Cash -1.4
PE High Last 5 Years -
Price To Book 0.7
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 0.7
Financial Strength
Total Debt To Equity 0.0
Int Coverage -
Current Ratio 11.0
Leverage Ratio 1.1
Quick Ratio 10.7
Long Term Debt To Capital 0.01
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -147.39
Return On Equity -158.87
Return On Capital -154.69
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
TENX
Tenax Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.